Bayer Fortifies Branding In OTC Naproxen Market With Win In Trademark Litigation
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Bayer convinces federal court to affirm USPTO appeal board decision to cancel competitor Belmora’s Flanax US naproxen product trademark because the firm used packaging that resembled a Bayer product with the same name sold in Mexico. The ruling could provide standing for owners of foreign marks to assert priority rights over similar US marks, according to a patent attorney.
You may also be interested in...
Degree Of Difficulty Climbs For Protecting Trademarks For US Brands In International Markets
Supreme Court finds presumption against extraterritorial reach of US laws, saying Congress never “affirmatively and unmistakably instructed” Lanham Act provisions apply to foreign conduct. Brands are known soon after launch in countries where they’re not marketed and some businesses likely see opportunities.
Perrigo's 'Inversion' Of Flonase Trademark Cuts Too Close For Glaxo's Market Share Comfort
Glaxo says it distributed more than $330m in Flonase Allergy Relief in 2015, its first year available as the second-in-category corticosteroid nasal spray, but argues that Nasoflow, Perrigo's brand for a generic equivalent, unfairly will encroach on its sales and market share.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.